Shuman Harry, an insider at Merus NV (MRUS), sold 11,002 shares of the company on November 24, 2025, at a price of $95.92 per share. This transaction totaled $1.06 million. Following this sale, Harry retains an equal number of shares in the biotechnology firm.
Merus NV, based in Utrecht, specializes in developing bispecific antibody therapeutics aimed at treating cancer. The company operates in both the Netherlands and the United States, employing around 260 staff. Its pipeline includes innovative products designed to engage cancer antigens and leverage the immune system to combat tumors. Notably, one of its key drugs, zenocutuzumab (Zeno), targets solid tumors, including those in the lung and pancreas.
With a current market capitalization of $7.3 billion and a trailing twelve-month EPS of -5.34, Merus NV is preparing for its upcoming earnings report on May 5, 2026, where analysts estimate an EPS of -1.42 and revenue of $11.1 million.
Insider transactions like this one provide transparency into executive actions but should be viewed in context. Selling can result from various personal factors such as diversification or tax planning, and does not inherently signal negative sentiment towards the company. Investors are encouraged to consider broader patterns of insider activity and other fundamental factors when assessing these signals.